Literature DB >> 6188377

Pulmonary complications associated with combination chemotherapy programs containing bleomycin.

K A Bauer, A T Skarin, J P Balikian, M B Garnick, D S Rosenthal, G P Canellos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6188377     DOI： 10.1016/0002-9343(83)91009-4

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  9 in total

Review 1.  Treating cancer patients. Practical monitoring and management of therapy-related complications.

Authors:  M Brigden; M McKenzie
Journal:  Can Fam Physician       Date:  2000-11       Impact factor: 3.275

2.  Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats.

Authors:  J G Hay; P L Haslam; A Dewar; B Addis; M Turner-Warwick; G J Laurent
Journal:  Thorax       Date:  1987-05       Impact factor: 9.139

3.  Bleomycin-induced pulmonary fibrosis in a patient with rheumatoid arthritis. A possible synergistic effect?

Authors:  M L Aitken; C Dugowson; R A Schmidt; M Fer
Journal:  West J Med       Date:  1989-03

Review 4.  Mechanisms of bleomycin-induced lung damage.

Authors:  J Hay; S Shahzeidi; G Laurent
Journal:  Arch Toxicol       Date:  1991       Impact factor: 5.153

Review 5.  Complications associated with chemotherapy in testicular cancer management.

Authors:  Chunkit Fung; David J Vaughn
Journal:  Nat Rev Urol       Date:  2011-03-15       Impact factor: 14.432

Review 6.  Long-term complications of chemotherapy for germ cell tumours.

Authors:  Uzair B Chaudhary; Jason R Haldas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

7.  Acute respiratory distress syndrome after chemotherapy for lung metastases from non-seminomatous germ-cell tumors.

Authors:  C Kirch; F Blot; K Fizazi; B Raynard; C Theodore; G Nitenberg
Journal:  Support Care Cancer       Date:  2003-06-03       Impact factor: 3.603

8.  Bleomycin-induced lung injury in the rat: effects of the platelet-activating factor (PAF) receptor antagonist BN 52021 and platelet depletion.

Authors:  T W Evans; R J McAnulty; D F Rogers; K F Chung; P J Barnes; G J Laurent
Journal:  Environ Health Perspect       Date:  1990-04       Impact factor: 9.031

9.  Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma.

Authors:  K I Lei; W T Leung; P J Johnson
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.